Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
The purpose of this study is to evaluate the clinical response of the tumors within the
 bladder of recurrent NMIBC patients to Mitomycin-C embedded in UroGen Pharma's (known at that
 time as TheraCoat Ltd.) TC-3 Sterile Hydrogel (TC-3) and to evaluate the patency of ureters 6
 hr post instillation.
An open label, successive dose escalation trial in subjects with Non Muscle Invasive Bladder
 Cancer (NMIBC), designed to evaluate the clinical response of low-intermediate risk tumors
 within the bladder to Mitomycin-C embedded in TC-3 Sterile Hydrogel (TC-3), administered
 intravesically, prior to TURBT in NMIBC subjects.

 Eligible subjects with NMIBC will be recruited to the trial following the initial diagnostic
 cystoscopy. During the diagnostic cystoscopy, the number of tumor lesions, their size and
 location will be documented and recorded with video or photo cystoscopy.

 A baseline cystoscopy will be conducted in all subjects for the evaluation of number of
 tumors and their diameters, and for mapping of their location. Baseline blood samples for
 liver and renal functions, as well as for complete blood count (CBC) and coagulation tests
 will be drawn prior to instillation to ensure eligibility and to serve as a reference point
 for systemic safety follow-up.

 A future TURBT has been planned for 8-10 weeks post screening. Enrolled subjects will be
 treated successively with 40mg MMC in 40 mL TC-3 (the first 6 subjects) and with 80 mg MMC in
 40 mL TC-3 (the following 12 subjects). At treatment session initiation, an 18-20 Fr two-way
 catheter will be inserted into the subject's bladder in order to completely empty the bladder
 of urine. Thereafter, a volume of 40 mL of cooled TC-3 mixed with 40 mg or 80 mg of MMC will
 be instilled through the catheter into the bladder of the subject. The catheter will then be
 ligated for twenty minutes, after which it will be drawn out of the bladder and the subject
 was will be allowed to urinate freely.

 The subjects will undergo six weekly bladder instillations according to their assigned
 treatment of either 40 mg MMC (Group A) or 80 mg MMC (Group B) in 40 mL of TC-3. Following
 completion of instillation treatment series, there will be a 2-4 weeks healing period prior
 to next follow up visit (overall 10-12 weeks post screening). During 2-4 weeks follow-up (FU)
 visit, the lesions' status will be examined under cystoscopy. For subjects who will appear to
 have complete response (CR), this will be confirmed based on histological results. For
 subjects that will not be classified as having CR, decision about performance of TURBT or
 giving additional treatment will be at the PI's discretion.

 Following 2-4 week FU visit, subjects will be managed according to their local standard
 guidelines. All patients will attempt to be followed up for 12 months following 2-4 weeks FU
 within the trial. These visits will be documented and data regarding recurrence and
 progression will be collected. Moreover, biopsy slides prior (when available), and following
 treatment will be collected and analyzed by an independent uro-pathologist.
Main Inclusion criteria:

 1. Single or multiple tumors (n≤7)

 2. Recurrent or Naive tumor.

 3. No prior history of T1 and/or Tis

 4. At least one tumor >1mm.

 5. Largest tumor diameter ≤ 30mm

 6. Cystoscopic appearance of papillary Low or high grade tumor

 Main Exclusion Criteria:

 1. Carcinoma In Situ (CIS)

 2. Over 7 lesions

 3. Lesion is larger than 30mm in diameter

 4. Cystoscopic appearance suspicious for Tis

 5. Tumor located in prostatic urethra

 6. Previous systemic chemotherapy or pelvic radiotherapy.